ResMedMEX:RMD 99 Gross Margin % is 62.25% as of Mar. 2026, which is 9% above its 10-year median of 57.18. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,059.75 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 806 Medical Devices & Instruments companies, ResMed ranks better than 64.76% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. ResMed's Gross Profit for the
three
months ended in Mar. 2026 was MXN16,067 Mil. ResMed's Revenue for the
three
months ended in Mar. 2026 was MXN25,812 Mil. Therefore, ResMed's Gross Margin % for the quarter that ended in Mar. 2026 was 62.25%.
The historical rank and industry rank for ResMed's Gross Margin % or its related term are showing as below:
MEX:RMD'
s Gross Margin % Range Over the Past 10 Years
Min: 55.78 Med: 57.18 Max: 61.59
Current: 61.59
During the past 13 years, the highestGross Margin % of ResMed was 61.59%. The lowest was 55.78%. And the median was 57.18%.
MEX:RMD's Gross Margin % is ranked better than 64.76% of 806
companies
in the Medical Devices & Instruments industry
Industry Median: 51.985
vs MEX:RMD: 61.59
ResMed had a gross margin of 62.25% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for ResMed was 0.10% per year.
ResMed (MEX:RMD) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ResMed had a gross margin of 62.25% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ResMed Gross Margin % Related Terms
ResMed Gross Margin % Historical Data
* Premium members only.
The historical data trend for ResMed's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RMD vs MDLN, WST, BDX: Gross Margin % Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ResMed's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ResMed (MEX:RMD) has a Gross Margin % of 62.25% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on ResMed and its competitors. This is near median its historical median of 57.18. Over the past decade, ResMed's Gross Margin % has ranged from 55.78 to 61.59. According to the industry distribution chart, ResMed ranks #284 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 35.2%.
Is ResMed's Gross Margin % too high?
ResMed's current Gross Margin % of 62.25% is near median its 10-year median of 57.18. Over the past 10 years, this metric has ranged from a low of 55.78 to a high of 61.59. The Medical Devices & Instruments industry median Gross Margin % is 51.99. ResMed's value of 62.25% is 19.7% above this industry median. Based on the distribution chart, ResMed ranks #284 out of 806 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ResMed has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Gross Margin % compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #284 out of 806 companies for Gross Margin %. This puts ResMed in the upper half of its industry. The industry median Gross Margin % is 51.99. ResMed's value of 62.25% is 19.7% above this benchmark. Historically, ResMed's own Gross Margin % has ranged from 55.78 to 61.59 over the past decade. While the company's 10-year median is 57.18 vs. the industry median of 51.99, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.99, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current Gross Margin % of 62.25% is 19.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current Gross Margin % is 62.25%, which is near median its own 10-year median of 57.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,059.75, compared to a current price of MXN3,716.10 — trading 26.6% below its estimated fair value. The current Gross Margin % is 62.25%, which is near median its 10-year median of 57.18 and 19.7% above the Medical Devices & Instruments industry median of 51.99. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Gross Margin % is 62.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,716.10 is trading 26.6% below its estimated GF Value™ of MXN5,059.75.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for MEX:RMD:
Gross Margin %: 62.25% (near median its 10-year median of 57.18)
GF Value™: MXN5,059.75 vs. price of MXN3,716.10 (26.6% below fair value)
Industry Position: 19.7% above the Medical Devices & Instruments median (#284 of 806)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
